Integra Lifesciences (IART)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2022 | 06-2022 | 03-2022 | 12-2021 | 09-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 511,937 | 447,152 | 407,092 | 513,448 | 470,231 |
| Receivables | 248,268 | 237,361 | 234,010 | 231,831 | 222,232 |
| Inventories | 311,060 | 320,208 | 328,005 | 317,386 | 327,167 |
| Other current assets | 1,831 | 30,525 | 0 | 0 | 0 |
| TOTAL | $1,196,453 | $1,137,414 | $1,066,053 | $1,153,716 | $1,103,785 |
| Non-Current Assets | |||||
| PPE Net | 300,729 | 302,423 | 309,209 | 311,703 | 293,921 |
| Intangibles | 2,031,895 | 2,072,681 | 2,130,899 | 2,159,031 | 2,167,876 |
| Other Non-Current Assets | 277,936 | 240,344 | 165,836 | 157,933 | 208,883 |
| TOTAL | $2,610,560 | $2,615,448 | $2,605,944 | $2,628,667 | $2,670,680 |
| Total Assets | $3,807,013 | $3,752,862 | $3,671,997 | $3,782,383 | $3,774,465 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 80,732 | 69,498 | 88,371 | 61,837 | 59,600 |
| Accrued Expenses | 147,618 | 155,002 | 162,819 | 213,114 | 184,564 |
| Other current liabilities | 6,364 | 7,728 | 5,343 | 5,295 | 5,388 |
| TOTAL | $304,452 | $295,596 | $315,833 | $340,021 | $332,858 |
| Non-Current Liabilities | |||||
| Long Term Debt | 920,530 | 932,154 | 936,772 | 936,757 | 935,436 |
| Other Non-Current Liabilities | 787,874 | 802,908 | 747,562 | 775,013 | 804,159 |
| TOTAL | $1,778,147 | $1,796,349 | $1,740,967 | $1,757,558 | $1,809,920 |
| Total Liabilities | $2,082,599 | $2,091,945 | $2,056,800 | $2,097,579 | $2,142,778 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 83,518 | 83,504 | 83,135 | 83,243 | 84,700 |
| Common Shares | 903 | 903 | 900 | 896 | 896 |
| Retained earnings | 826,172 | 776,257 | 731,469 | 698,568 | 653,184 |
| Other shareholders' equity | -7,302 | -13,095 | -20,911 | -45,603 | -47,223 |
| TOTAL | $1,724,414 | $1,660,917 | $1,615,197 | $1,684,804 | $1,631,687 |
| Total Liabilities And Equity | $3,807,013 | $3,752,862 | $3,671,997 | $3,782,383 | $3,774,465 |